Compare WIX & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIX | PBLS |
|---|---|---|
| Founded | 2006 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2013 | 2026 |
| Metric | WIX | PBLS |
|---|---|---|
| Price | $73.90 | $31.20 |
| Analyst Decision | Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $134.67 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 657.2K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.80 | N/A |
| Revenue Next Year | $13.21 | N/A |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $25.56 |
| 52 Week High | $181.11 | $42.49 |
| Indicator | WIX | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 35.58 |
| Support Level | $69.27 | $26.42 |
| Resistance Level | $82.71 | $33.65 |
| Average True Range (ATR) | 4.99 | 3.10 |
| MACD | -1.22 | -0.94 |
| Stochastic Oscillator | 32.95 | 12.31 |
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years, it has invested heavily and introduced its Wix Studio offering for partners, which are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.